Engineering of Clostridium novyi to enhance efficacy in cancer therapy
Publication Date
December 10, 2025
Creator
Abstract
Clostridium novyi-NT (non-toxic) is an attenuated clone derived from C. novyi, rendered non-pathogenic through the removal of a resident phage that carries the gene for the lethal alpha toxin. It is a Gram-positive spore-forming bacterium, which has gained significant attention for its potential use in cancer therapy. C. novyi-NT is a strictly anaerobic bacterium, enabling it to thrive in the hypoxic regions of tumours, a characteristic hallmark of solid malignancies. For therapy, C. novyi-NT can be delivered as dormant spores that germinate in hypoxic, necrotic tumours, inducing oncolysis through enzymatic activity and immune activation, while complementing treatments that target oxygen-rich tumour areas.
This study focused on genetically modifying C. novyi-NT to improve its safety profile for use in cancer therapeutics, and to improve its efficacy. Prior to modifying the organism for cancer therapeutics, gene transfer into C. novyi-NT and its molecular characteristics were assessed. Various strategies, including gene knockouts and altering donor methylation patterns, were used to bypass restriction-modification barriers, but showed no effect.
To enhance the safety profile of C. novyi-NT conditionally sporulating strains were created using CRISPR-Cas technology, whereby the strains were only able to sporulate when in the presence of specific ligands. This approach provided a solution for preventing the spread of spores beyond the targeted tumour region, thereby reducing the risk of toxicity and the dissemination of recombinant spores.
The promoters of C. novyi-NT were investigated, and reporter assays identified a suitable candidate for cytokine expression. C. novyi-NT was subsequently engineered to express the cytokines GM-CSF and IL-4, with the investigation of signal peptides resulting in the efficient secretion of GM-CSF.
Furthermore, a novel inducible xylose promoter was engineered for use in both E. coli and C. novyi-NT to control toxicity, which could facilitate the advancement of cytokine expression and cloning in future studies.
Item Type
ethesis
Thesis Type
PhD
Supervisors
Subjects (LC)
Associated Schools / Departments
School of Life Sciences
eprints ID
82885
UoN Repository URI
Except where otherwise noted, this item's license is described as
File(s)![Thumbnail Image]()
Name
RICHARDS_Danielle Thesis-with-corrections.pdf
Type
Full-text
Description
Examined. Corrected version
Size
4.63 MB
Format
Adobe PDF
Checksum (MD5)
e53005946683eb80bcc27b436d61505c